Orihuela

Researchers are evaluating whether a structured training program for intensive care unit (ICU) staff can reduce health problems known as post-intensive care syndrome (PICS) in adults after an ICU stay. PICS includes new or worsening physical, cognitive, and emotional difficulties that affect daily life, independence, memory, mood, and quality of life. The study also compares training on the standard ABCDEF care bundle with an expanded A-Z care bundle to see if the broader approach offers additional benefits in preventing PICS. The study involves a structured educational program for ICU teams, delivered through online courses, face-to-face sessions, checklists, pocket guides, and visual reminders. Two groups are trained: one on the classic ABCDEF bundle and another on the expanded A-Z bundle, which adds care aspects like nutrition, sleep, infection prevention, safety, discharge planning, and psychological support. At least 75% of staff in each ICU complete the training. After training, ICUs continue usual care while applying the trained care bundles and documenting adherence. Participants are adults who have stayed in the ICU for at least 48 hours and survived hospital discharge. They will be followed up at 1, 3, 6, and 12 months after discharge through tests and questionnaires about physical health, cognition, mood, and quality of life. The main measure is the presence of PICS three months after discharge. The study also monitors adherence to care practices and compares outcomes before and after training, as well as between the two training groups.

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Researchers are evaluating the efficacy and safety of Beltavac4, a subcutaneous immunotherapy using a polymerized extract from house dust mites, in people aged 12 to 65 who have allergic rhinitis or rhinoconjunctivitis, with or without asthma. This Phase 3 trial focuses on those with moderate to severe persistent symptoms and confirmed sensitization to specific dust mite allergens. The study aims to better understand how this treatment impacts allergy symptoms and medication use over time. Participants will receive either Beltavac4 or a placebo, both given through monthly injections over one year following a rush schedule. This means each participant will have one vaccine administration each month for 12 months. The treatment compares the effects of the active vaccine against a placebo to assess benefits and safety. During the study, participants will be monitored regularly. Researchers will measure combined nasal symptoms and medication use throughout the 12 months of treatment. Safety assessments and symptom tracking will occur during the screening phase and throughout the treatment period. The total participation includes these monthly visits and follow-ups to observe the treatment's impact on allergic conditions.

Researchers are evaluating inhaled sedation with isoflurane via the Sedaconda ACD-S system compared to intravenous sedation with propofol in critically ill patients who require mechanical ventilation. This phase IV, multicenter, randomized controlled trial focuses on patients expected to need more than 48 hours of invasive mechanical ventilation and aims to assess if isoflurane can reduce the duration of mechanical ventilation and ICU stay compared to propofol. Isoflurane has shown potential advantages in sedation but its long-term effects and outcomes in ICU patients are not fully understood. Participants will be randomly assigned to one of two groups: one receiving inhaled sedation with isoflurane administered via the Sedaconda ACD device and the other receiving intravenous sedation with propofol. Both treatments are administered to maintain a deep sedation level with a Richmond Agitation Sedation Scale (RASS) score between -3 and -5. The study includes 620 patients across 22 centers. The primary period involves sedation during mechanical ventilation, with monitoring continuing through the first 28 days after randomization. During the study, researchers will track ventilator-free days up to day 28 after randomization as the primary outcome. Secondary assessments include ICU-free days at day 28, time to extubation after sedation withdrawal, effectiveness in maintaining target sedation levels, need for additional hypnotics, delirium incidence and duration at day 28, and evaluations of mental, cognitive, and quality of life status at 90 days post-hospital discharge. Safety and efficacy data will be collected through clinical monitoring and cognitive assessments throughout the study period.

Researchers are evaluating the safety and effectiveness of Beltaven, a subcutaneous allergen-specific immunotherapy, in patients allergic to Apis mellifera, Polistes dominula, or Vespula species. This prospective, open, multi-center non-interventional study includes both children aged 14 years and older and adults, and it takes place in routine medical care settings. The study aims to understand how well Beltaven works and how safe it is when used to treat these specific insect sting allergies. The treatment involves administering Beltaven subcutaneously following a dosing schedule clustered over three weeks. The study observes patients who have positive allergy tests and who are willing to receive this immunotherapy. No additional interventions or comparator groups are mentioned, as this is an observational study focusing on real-world use of the therapy. Participants are monitored for clinical effectiveness over a period of 9 months after the initial dosing. Assessments include safety and treatment response, with evaluations based on allergy testing and patient reactions. The study collects data during routine medical visits without altering standard care, aiming to provide insight into the therapy's performance in everyday clinical practice.